A share price of Arcus Biosciences Inc [RCUS] is currently trading at $18.37, up 7.43%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RCUS shares have gain 10.33% over the last week, with a monthly amount glided 5.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on October 08, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $29. Previously, BofA Securities started tracking the stock with Neutral rating on November 18, 2022, and set its price target to $33. On October 11, 2022, Morgan Stanley initiated with a Overweight rating and assigned a price target of $40 on the stock. Berenberg initiated its recommendation with a Buy and recommended $50 as its price target on November 24, 2020. In a note dated April 03, 2020, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $21 on this stock.
Arcus Biosciences Inc experienced fluctuations in its stock price throughout the past year between $12.95 and $20.31. Currently, Wall Street analysts expect the stock to reach $34.29 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $18.37 at the most recent close of the market. An investor can expect a potential return of 86.66% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Trailing Twelve Months sales for Arcus Biosciences Inc [NYSE:RCUS] were 247.00M which represents 34.48% growth. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -1.19%, Pretax Profit Margin comes in at -1.0%, and Net Profit Margin reading is -1.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.43 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.37 points at the first support level, and at 16.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.89, and for the 2nd resistance point, it is at 19.40.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcus Biosciences Inc [NYSE:RCUS] is 5.14. In addition, the Quick Ratio stands at 5.14 and the Cash Ratio stands at 0.78. Considering the valuation of this stock, the price to sales ratio is 6.80, the price to book ratio is 2.64.
Transactions by insiders
Recent insider trading involved Azoy Alexander, Chief Accounting Officer, that happened on Aug 13 ’24 when 1357.0 shares were sold. Chief Operating Officer, Jarrett Jennifer completed a deal on Mar 27 ’24 to sell 11551.0 shares. Meanwhile, Chief Operating Officer Jarrett Jennifer sold 13449.0 shares on Mar 18 ’24.
